REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
08/25/2025
Back to search
Official data from USPTO
CYZEQIVA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
08/26/2025
Trademark type
Combined
Nice classes
5
Filing date
08/21/2019
Registration date
08/25/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/25/2020
Last transaction
08/26/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
24
Owner location
SG
Examiner
MIRANDA, JOHN
Law office
N20
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a stylized green circular design featuring white branch-like designs and seven yellow, fuzzy orbs of various sizes. To the right of the design is the stylized green wording "CYZEQIVA". The white background is for background purposes only and is not claimed as a feature of the mark.
Holders and representatives
Holders
PRESTIGE BIOPHARMA PTE. LTD.
Representatives
Jonathan G. Morton
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Antibodies for medical purposesmedical preparations for the treatment of malignant tumors; biological preparations for medical purposesmedical preparations for the treatment of malignant tumors; biological preparations for pharmaceutical purposesmedical preparations for the treatment of malignant tumors; drugs for medical purposesmedical preparations for the treatment of malignant tumors; medicines for human usemedical preparations for the treatment of malignant tumors; monoclonal antibodies for medical usemedical preparations for the treatment of malignant tumors; pharmaceutical drugsmedical preparations for the treatment of malignant tumors; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparationspharmaceutical preparations for the treatment of malignant tumors; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for treating malignant tumors; tumor suppressing agents
Publications
History of USPTO decisions and trademark events.
22 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/04/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/11/2020
FIMP
FINAL DISPOSITION PROCESSED
12/11/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/25/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
08/25/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/09/2020
PUBO
PUBLISHED FOR OPPOSITION
06/09/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/20/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/30/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/29/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/29/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/29/2020
RFNT
REFUSAL PROCESSED BY IB
01/10/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/21/2019
RFRR
REFUSAL PROCESSED BY MPU
12/21/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/27/2019
CNRT
NON-FINAL ACTION WRITTEN
11/26/2019
MAFR
APPLICATION FILING RECEIPT MAILED
11/23/2019
DOCK
ASSIGNED TO EXAMINER
11/20/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/19/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/14/2019
Continuous trademark protection
Get notified about every new filing that threatens CYZEQIVA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.